Search 

Sareum is a clinical-stage small molecule company actively involved in developing next-generation kinase inhibitors to treat autoimmune diseases and cancer.

We recognise the crucial role of the TYK/JAK kinase cell signalling family in maintaining a healthy immune system, and our pipeline is primarily focused on this area of scientific and commercial interest.

Scendea is a leading product development and regulatory consulting practice serving the pharmaceutical and biotechnology industry. We are adept at solving complex issues associated with medicinal product development and offer strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory. Our industry experience is demonstrable, having been involved in over 1,000 development programmes in the US and Europe over the last twenty years. As is our scientific excellence, with a team that includes ex-regulators, high-calibre academics and clinician scientists. Our technical regulatory expertise spans the entire product development spectrum from pre-clinical to marketing authorisation.

Scottish Development International is Scotland's trade and inward investment agency. We help businesses from around the world do business in or with Scotland.

If you’re an overseas business looking to set up in Scotland or source Scottish products, services or innovation, we can help.

At Silence, we aim to transform peoples’ lives around the world by silencing diseases through our precision engineered medicines and driving positive change for the communities around us. As pioneers in the design and development of siRNAs (short interfering RNAs), we are advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options.

Exhibiting at booth 50 with the UK delegation, Sphere Fluidics is developing picodroplets and single cell analysis systems and services for therapeutic discovery.

Specialities
Biopharmaceutical, lab-on-a-chip, cells, antibodies, microfluidics, enzymes, cancer, biologics, biotechnology, pharmaceutical, life sciences, immunology, oncology, cell therapies, and stem cells

Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services CRO. Founded in 2004 and private equity-backed since 2017, we operate a fully-enabled research facilities in Nottingham and Alderley Park, UK housing over 500 staff (80% of our scientists have PhDs). Our experienced R&D scientists possess all the professional skills and know-how required to undertake the most demanding of drug discovery and/or pre-clinical development projects and drive them from target validation, through hit identification, hit-to-lead and lead optimization to development candidate. Sygnature collaborates with its partners via risk share and FTE-based collaborations.

Yet, the demand for new CNS treatments is increasing and is likely to continue to do so.

The Science Behind helps Sponsors and CROs with some of these challenges in Phase 1 trials by providing the tools and specialist expertise to answer key questions in relation to safety and efficacy when bringing novel drug candidates to human clinical trials.